Antibiotic discovery in the age of structural biology - a comprehensive overview with special reference to development of drugs for the treatment of Pseudomonas aeruginosa infection

Alessa Koehnke; Reinhard E Friedrich

Antibiotic discovery in the age of structural biology - a comprehensive overview with special reference to development of drugs for the treatment of Pseudomonas aeruginosa infection

Standard

Antibiotic discovery in the age of structural biology - a comprehensive overview with special reference to development of drugs for the treatment of Pseudomonas aeruginosa infection. / Koehnke, Alessa; Friedrich, Reinhard E.

In: IN VIVO, Vol. 29, No. 2, 21.03.2015, p. 161-7.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Koehnke, A & Friedrich, RE 2015, 'Antibiotic discovery in the age of structural biology - a comprehensive overview with special reference to development of drugs for the treatment of Pseudomonas aeruginosa infection', IN VIVO, vol. 29, no. 2, pp. 161-7.

APA

Koehnke, A., & Friedrich, R. E. (2015). Antibiotic discovery in the age of structural biology - a comprehensive overview with special reference to development of drugs for the treatment of Pseudomonas aeruginosa infection. IN VIVO, 29(2), 161-7.

Vancouver

Koehnke A, Friedrich RE. Antibiotic discovery in the age of structural biology - a comprehensive overview with special reference to development of drugs for the treatment of Pseudomonas aeruginosa infection. IN VIVO. 2015 Mar 21;29(2):161-7.

Bibtex

@article{1d5b15531dac49fc9818edd6bbf7191e,

title = "Antibiotic discovery in the age of structural biology - a comprehensive overview with special reference to development of drugs for the treatment of Pseudomonas aeruginosa infection",

abstract = "Due to the persistence and spread of antibiotic resistance, the discovery and exploitation of new antibiotic targets should be the subject of intensive research. Effective strategies are required to develop antibiotic alternatives. Antibiotics that act on new targets or via novel mechanisms have the greatest likelihood of overcoming resistance. In particular, there is a lack of specific antibiotics for Pseudomonas aeruginosa, one of the leading causes of healthcare-associated infections, exhibiting high resistance levels. Herein we describe how structure-based drug design can be used to achieve new antibiotics for the treatment of Pseudomonas aeruginosa infection, using an essential enzyme of the fatty acid synthesis pathway from P. aeruginosa as an example.",

keywords = "Animals, Anti-Bacterial Agents, Bacterial Proteins, Drug Discovery, Drug Resistance, Bacterial, Humans, Incidence, Mutation, Pseudomonas Infections, Pseudomonas aeruginosa, Structure-Activity Relationship",

author = "Alessa Koehnke and Friedrich, {Reinhard E}",

year = "2015",

month = mar,

day = "21",

language = "English",

volume = "29",

pages = "161--7",

journal = "IN VIVO",

issn = "0258-851X",

publisher = "International Institute of Anticancer Research",

number = "2",

}

RIS

TY - JOUR

T1 - Antibiotic discovery in the age of structural biology - a comprehensive overview with special reference to development of drugs for the treatment of Pseudomonas aeruginosa infection

AU - Koehnke, Alessa

AU - Friedrich, Reinhard E

PY - 2015/3/21

Y1 - 2015/3/21

N2 - Due to the persistence and spread of antibiotic resistance, the discovery and exploitation of new antibiotic targets should be the subject of intensive research. Effective strategies are required to develop antibiotic alternatives. Antibiotics that act on new targets or via novel mechanisms have the greatest likelihood of overcoming resistance. In particular, there is a lack of specific antibiotics for Pseudomonas aeruginosa, one of the leading causes of healthcare-associated infections, exhibiting high resistance levels. Herein we describe how structure-based drug design can be used to achieve new antibiotics for the treatment of Pseudomonas aeruginosa infection, using an essential enzyme of the fatty acid synthesis pathway from P. aeruginosa as an example.

AB - Due to the persistence and spread of antibiotic resistance, the discovery and exploitation of new antibiotic targets should be the subject of intensive research. Effective strategies are required to develop antibiotic alternatives. Antibiotics that act on new targets or via novel mechanisms have the greatest likelihood of overcoming resistance. In particular, there is a lack of specific antibiotics for Pseudomonas aeruginosa, one of the leading causes of healthcare-associated infections, exhibiting high resistance levels. Herein we describe how structure-based drug design can be used to achieve new antibiotics for the treatment of Pseudomonas aeruginosa infection, using an essential enzyme of the fatty acid synthesis pathway from P. aeruginosa as an example.

KW - Animals

KW - Anti-Bacterial Agents

KW - Bacterial Proteins

KW - Drug Discovery

KW - Drug Resistance, Bacterial

KW - Humans

KW - Incidence

KW - Mutation

KW - Pseudomonas Infections

KW - Pseudomonas aeruginosa

KW - Structure-Activity Relationship

M3 - SCORING: Journal article

C2 - 25792642

VL - 29

SP - 161

EP - 167

JO - IN VIVO

JF - IN VIVO

SN - 0258-851X

IS - 2

ER -